Immuneering Shares Drop 23% Despite ASCO Data Showing 17.3-Month Survival
IMRX•Immuneering shares fell 23% after updated ASCO data showed median overall survival of 17.3 months for its pancreatic cancer candidate, more than double the 8.5-month standard. The drug achieved 8.3-month progression-free survival, 36% response rate and moves into Phase 3 dosing mid-2026.
1. Early-Stage Data Highlights
At the ASCO 2026 Annual Meeting, Immuneering presented updated early-stage data for its pancreatic cancer candidate, revealing a median overall survival of 17.3 months compared to an 8.5-month historical average; median progression-free survival reached 8.3 months, with a 36% objective response rate and 82% disease control rate, and no new safety signals.
2. Market Reaction
Shares of Immuneering slid 23% on the day of the presentation, on track for the steepest single-session decline since January, reversing prior gains and reflecting a sell-the-news reaction despite strong efficacy metrics.
3. Phase 3 Trial Plans
The company plans to begin dosing patients in a randomized Phase 3 trial in mid-2026, and analysts maintain an average 12-month price target implying near 200% upside, supported by unanimous Buy ratings among covering analysts and heightened retail bullish sentiment.
